Fulcrum Therapeutics Stock Price, News & Analysis

Fulcrum Therapeutics (NASDAQ: FULC) reported Q1 2025 financial results and business updates. The company completed enrollment in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial for pociredir in sickle cell disease and initiated the 20 mg dose cohort. Clinical data is expected in early Q3 2025 for the 12 mg cohort and by end of 2025 for the 20 mg cohort. The trial shows >90% drug adherence with no discontinuations. Financial highlights include: $226.6 million in cash/equivalents (vs $241.0M in Q4 2024), reduced R&D expenses of $13.4 million (vs $19.8M in Q1 2024), lower G&A expenses of $7.0 million (vs $10.1M in Q1 2024), and net loss of $17.7 million (vs $26.9M in Q1 2024). The company expects its current cash position to fund operations into at least 2027.

Fulcrum Therapeutics (FULC), a clinical-stage biopharmaceutical company specializing in small molecule development for rare genetic diseases, has scheduled its first quarter 2025 financial results release for Thursday, May 1, 2025, before U.S. market opening.

The company will host a conference call and webcast at 8:00 a.m. ET where management will present the quarterly results and provide corporate development updates. Participants can access the call through a registration link that will provide dial-in details and a unique PIN. The webcast will be available through the company's Investor Relations website.

Fulcrum Therapeutics (FULC), a clinical-stage biopharmaceutical company focused on developing small molecules for rare genetic diseases, has granted stock options to two new employees under its 2022 Inducement Stock Incentive Plan. The grants, announced on April 11, 2025, include an aggregate of 96,800 options with an exercise price of $2.72 per share, matching the closing price on April 7, 2025.

The options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first employment anniversary, followed by 6.25% vesting quarterly over the next twelve quarters, contingent on continued employment.

Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company developing small molecules for rare genetic diseases, has announced its participation in the Leerink Partners Global Healthcare Conference. The company's management will engage in a fireside chat on March 11, 2025 at 8:40 am ET in Miami, FL.

The presentation will be accessible via webcast through the company's website investor relations section and will remain available for replay for a minimum of 30 days following the event.

Fulcrum Therapeutics (Nasdaq: FULC) reported its Q4 and full year 2024 financial results, highlighting progress in its lead program, pociredir for sickle cell disease (SCD). The company has enrolled 10 patients in the 12 mg dose cohort of the Phase 1b PIONEER trial and expects to share clinical data from this cohort in mid-2025 and from the 20 mg dose cohort by year-end.

Financial highlights include $241.0 million in cash, cash equivalents, and marketable securities as of December 31, 2024, providing runway into at least 2027. Full-year 2024 collaboration revenue was $80.0 million, primarily from a Sanofi upfront payment. R&D expenses decreased to $63.4 million for 2024 (from $71.8 million in 2023), while G&A expenses fell to $36.4 million (from $41.7 million). Net loss for 2024 was $9.7 million, significantly reduced from $97.3 million in 2023.

Fulcrum also plans to submit an IND for Diamond-Blackfan anemia in Q4 2025 and will present data from its discontinued losmapimod program at the 2025 MDA Conference in March.

Fulcrum Therapeutics (FULC), a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases, has scheduled its fourth quarter and full year 2024 financial results release for Tuesday, February 25, 2025, before U.S. market opening.

The company will host a conference call and webcast at 8:00 a.m. ET on the same day, where management will discuss the results and provide updates on corporate developments. Participants can access the call through registration, and an audio webcast will be available through the company's Investor Relations website.

Fulcrum Therapeutics (FULC) has announced the granting of inducement stock options to a new employee under its 2022 Inducement Stock Incentive Plan. The company granted 63,000 options to purchase common stock at an exercise price of $3.81 per share, which was the closing price on February 3, 2025.

The options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first employment anniversary, followed by 6.25% vesting quarterly over the next twelve quarters. The vesting is contingent upon continued employment with Fulcrum through the applicable dates. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4).

Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company specializing in small molecule development for rare genetic diseases, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will engage in a fireside chat during the virtual event on February 12, 2025, at 1:20 pm ET.

Interested parties can access the webcast through a direct link or via the 'Events and Presentations' section of Fulcrum's investor relations website. The presentation recording will remain available for a minimum of 30 days following the event on the company's website.

Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company developing small molecules for rare genetic diseases, has announced its participation in three major healthcare conferences this December. The company will present at the Piper Sandler 36th Annual Healthcare Conference on December 3 with a fireside chat at 12:00 pm ET in New York, the Citi 2024 Global Healthcare Conference on December 4 in Miami, and the Evercore ISI 7th Annual HealthCONx Conference on December 5 in Miami. The Piper Sandler fireside chat webcast will be available on Fulcrum's website for at least 30 days after the presentation.